Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer Declares First-Quarter 2015 Dividend

Business Wire December 15, 2014

OPKO and Pfizer Enter into Global Agreement for OPKO's Long-Acting Human Growth Hormone (hGH-CTP)

Business Wire December 15, 2014

Pfizer and Brenda Strong Encourage Women to Change the Conversation on Sexual Health Post-Menopause

Business Wire December 10, 2014

New Data at ASH 2014 Highlight Progress of Pfizer's Growing Portfolio in Blood Cancers

Business Wire December 9, 2014

Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects

Business Wire December 8, 2014

Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform

Business Wire December 8, 2014

Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative

Canada NewsWire December 4, 2014

Mylan receives tentative FDA approval for pediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative

PR Newswire December 4, 2014

New Survey Finds Majority of Women with Breast Cancer Who Work Want to Do So Even While Undergoing Treatment

Business Wire December 2, 2014

Pfizer Completes Acquisition of Baxter's Marketed Vaccines

Business Wire December 1, 2014

ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV

PR Newswire November 27, 2014

Nodality Develops Disease-Associated PD-1 Assay System for Application in Immuno-oncology

Business Wire November 19, 2014

TRUMENBA® (Meningococcal Group B Vaccine) is Now Available

Business Wire November 18, 2014

Nodality, Inc. Announces Data Presentation from Collaborative Program with UCB at American College of Rheumatology 2014 Annual Meeting

Business Wire November 18, 2014

Nodality, Inc. Announces Data Presentations from Systemic Lupus Erythematosus Collaborative Programs at American College of Rheumatology 2014 Annual Meeting

Business Wire November 17, 2014

Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)

GlobeNewswire November 17, 2014

Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

Business Wire November 17, 2014

Novel Agreement Expands Access to Pfizer's Contraceptive, Sayana® Press, for Women Most in Need in the World's Poorest Countries

Business Wire November 13, 2014

Pfizer Highlights Leadership in Rheumatology and Inflammation with Data to be Presented at the ACR/ARHP 2014 Annual Meeting

Business Wire November 12, 2014

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Business Wire November 5, 2014